CYP19A1 and adenomyosis: The increased aromataseactivity in adenomyotic tissue (Kitawaki etal., 1997) has led to the use of aromatase inhibitors (AI)in symptomatic women with adenomyosis undergoing IVF (Kimura et al., 2007; Badawy et al., 2012; Sharma et al., 2023).